Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small…
Consensus price target: $2.00 (-90.91% downside from $22.00)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $8.5M | +4192.93% | $-10.94M |
| 2024 | $198K | -75.88% | $-53.86M |
| 2023 | $821K | +154.18% | $-172.6M |
Stock data for APLM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics